Enbloc Resection of Bladder Tumor in treatment of Non–Muscle Invasive Bladder Cancer

Background: Bladder cancer is still the most common cancer of the bladder tract and the ninth most common cancer in the world. Most people who get bladder cancer have nonmuscle invasive bladder cancer (NMIBC), which has a much lower death rate than muscle invasive bladder cancer. Urologists are now more interested in enbloc removal of bladder tumor (ERBT), but there are only a few small studies that look at hydrodissemination during ERBT. ERBT gives a lot of detrusor muscle samples (more than 95%) and good samples for figuring out what's wrong. So far, it hasn't been looked into whether second resections can be avoided. All energy tools, like lasers and electric cautery, have been used to do ERBT with the same positive effects on the patient and the cancer. Conclusion: The numbers show that there isn't a big difference between normal and perioperative morbidity transurethral resection of bladder tumors, but only a few of the papers used a structured way to group them. There are no conclusions that can be made about how ERBT affects recurrence.